FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch
Merck has been handed a rare setback at the FDA.
After filing for the accelerated approval of a combination of their star PD-1 drug Keytruda …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
